Metered Research Formulation
NAD+ Research Formulation
A 2,250 mg metered research formulation powered by GW Bio Health R3a Cold Fusion™ delivery technology.
$135.00
In Stock
For Research Use Only — Not For Human Or Veterinary Use
Powered by GW Bio Health Technology
R3a Cold Fusion™ Metered Delivery Platform
Authorized Elev8 Health Distributor & Partner
Related Research Areas
Third-Party Tested
COA Documentation
Research-Grade
Batch Traceability
Elev8 NAD+ Research Formulation is a 2,250 mg metered research formulation built on the metered delivery technology developed by GW Bio Health.
Rather than functioning as a conventional liquid solution, the research formulation platform is engineered around molecular protection, metered precision, temperature-dependent gel formation, extended formulation residence, and gradual release under defined research conditions.
Each 30 mL bottle provides approximately 300 metered actuations containing 7.5 mg of NAD+ per actuation.
Technology descriptions are based on technical information supplied by GW Bio Health and describe the engineering rationale of the platform. They should not be interpreted as guaranteed outcomes.
Certificates of Analysis
COA coming soon
NAD+ Delivery, Reimagined
Not Just NAD+.
A Delivery Platform Built Around It.
GW Bio Health developed its R3a Cold Fusion™ research formulation platform around one central challenge: getting fragile molecules into a format that protects the active while extending the formulation's residence characteristics.
The Elev8 NAD+ Research Formulation uses this specialized delivery architecture rather than an ordinary water-based solution.
Liquid Formulation
Metered Actuation
SolGel Transition
Formulation Residence
Gradual Release
Illustrative representation of the platform's formulation rationale. This diagram describes engineering objectives under defined research conditions, not guaranteed outcomes.
2250 MG
Total NAD+
~300
Metered Actuations
7.5 MG
Per Actuation
~30 MIN*
Designed Formulation Residence
*Approximate engineered formulation residence window described by GW Bio Health under defined research conditions.
The Four Core Technologies
Engineered as a Platform
GW Bio Health's R3a / Cold Fusion™ approach combines four design principles into a single metered research formulation format.
R3a Protective Shield™
Molecular Protection
GW Bio Health describes R3a as a protective delivery environment surrounding free NAD+ molecules rather than a conventional encapsulation system.
The platform is designed to reduce exposure of the active to destabilizing environmental factors such as light, oxygen, and water-driven degradation.
Precision Jet Delivery
Metered. Targeted. Consistent.
The metered applicator uses a calibrated actuator designed to deliver a consistent, repeatable metered output. Each 30 mL bottle contains approximately 300 metered actuations at 7.5 mg NAD+ per actuation.
Reverse-Thermal SolGel
Liquid During Actuation. Gel Above Threshold.
The formulation is engineered as a thermosensitive system. It remains liquid during metered actuation and is designed to undergo a temperature-dependent phase transition toward a bioadhesive SolGel above approximately 85°F. This transition is intended to support formulation stability and extended residence rather than immediate runoff under defined research conditions.
Extended Formulation Residence
An Engineered Residence Property
GW Bio Health describes the SolGel matrix as engineered to resist runoff across an approximately 30-minute designed formulation residence window — a formulation property studied under controlled conditions, in contrast to a conventional liquid formulation.
~30 Minute
Designed Formulation Residence Window
How the Technology Works
Five Engineered Steps
Protect
NAD+ is incorporated into GW Bio Health's R3a protective formulation environment.
Meter
A calibrated actuator dispenses a defined amount of formulation per actuation.
Dispense
The formulation leaves the metered applicator as a fine, consistent liquid output.
Transition
Above its defined transition threshold, the thermosensitive formulation is designed to convert into a bioadhesive SolGel.
Reside + Release
The SolGel is engineered to resist immediate runoff and release the formulation gradually across an approximately 30-minute designed formulation residence window.
Delivery-System Research
Formulation Research Focus
Thermosensitive gel systems, formulation residence characteristics, and controlled-release matrices are active areas of published delivery-system research, independent of any finished product.
GW Bio Health engineered the MitoJet™ / R3a research formulation platform around these formulation properties: protecting the active, maintaining stability, and extending formulation residence rather than allowing immediate runoff.
Phase-Transition Behavior
Temperature-dependent conversion from liquid to bioadhesive SolGel under defined conditions.
Formulation Residence
Engineered resistance to immediate runoff, studied as a formulation property.
Gradual Release
Controlled-release characteristics of the SolGel matrix over a defined window.
Platform Rationale
The engineering objective behind the formulation design.
Finished-Product Data
A separate, higher bar requiring testing of this exact formulation.
Discussion of phase-transition and residence behavior describes the engineering rationale of the formulation platform. It is not a claim about outcomes for this finished research formulation.
A Different Approach to Metered Delivery
Why the Delivery Architecture Is Different
Conventional Liquid Formulation Format
- Remains primarily liquid
- Prone to rapid runoff
- Shorter formulation residence
- Standard solution architecture
- No thermosensitive phase transition
GW Bio Health R3a / Cold Fusion™
- Protective formulation environment
- Precision metered delivery
- Reverse-thermal SolGel design
- Engineered bioadhesive matrix
- Designed for extended formulation residence
- Gradual-release formulation approach
This comparison describes differences in formulation architecture and engineering design. It is not a statement that one approach is superior for any specific outcome.
Why Protection Matters
Fragile Molecule.
Purpose-Built Environment.
NAD+ is a chemically sensitive molecule, and formulation stability is an important consideration when developing a delivery system around it.
GW Bio Health's Cold Fusion™ manufacturing and R3a formulation approach are designed to provide a protected environment for NAD+ while maintaining a practical metered research formulation format.
Light Exposure
Oxygen Exposure
Formulation Stability
Metered Precision
GW Bio Health utilizes controlled manufacturing practices intended to protect formulation integrity.
Why NAD+ Is Studied
NAD+ and Cellular Biology
Nicotinamide adenine dinucleotide — NAD+ — is an essential cellular coenzyme involved in numerous fundamental biochemical processes.
Cellular Energy
NAD+ participates in redox reactions involved in mitochondrial ATP production.
Sirtuin Activity
NAD+ serves as a required substrate for the sirtuin family of enzymes involved in metabolic and cellular signaling.
DNA Repair
NAD+ is consumed by PARP enzymes involved in cellular DNA-damage responses.
Mitochondrial Function
NAD+ / NADH balance plays an important role in mitochondrial metabolism and cellular energy pathways.
Cellular Aging Research
Age-associated changes in NAD+ metabolism are an active area of scientific investigation.
NAD+ metabolism is studied in relation to aging biology. This describes properties of the molecule as reported in scientific literature and is not a claim about any Elev8 finished product.
Why Elev8 Selected This Technology
Why Elev8 Chose GW Bio Health
At Elev8 Health, we believe the delivery system deserves the same attention as the molecule itself.
That philosophy is why we partnered with GW Bio Health for our NAD+ research formulation platform.
GW Bio Health engineered MitoJet™ around a combination of molecular protection, precision metered delivery, thermosensitive bioadhesive behavior, and extended formulation residence.
For Elev8, this represents a fundamentally different research format from simply placing NAD+ into a conventional liquid solution.
The Active Matters.
The Delivery System Matters Too.
Our Technology Partner
Technology Partner
GW Bio Health is the developer of the R3a Nano-Fusion™ delivery platform, Cold Fusion™ formulation technology, and MitoJet™ NAD+ research formulation platform.
Elev8 Health participates as an approved distributor and partner for this NAD+ technology.
GW Bio Health provides the underlying formulation and delivery science, while Elev8 Health brings the technology to the Elev8 platform through our branded research catalog.
Technology and intellectual-property rights remain with their respective owners.
Same Platform. Elev8 Identity.
GW Bio Health's partner program allows approved brands to offer formulations built on its underlying delivery platform through their own customer channels. The Elev8 NAD+ Research Formulation is offered through this partnership model while retaining the Elev8 Health brand experience.
Technology By
GW Bio Health
MitoJet™ · R3a · Cold Fusion™
Research Library
Organized by Evidence Category
We keep four types of information clearly separated so molecule research, delivery science, platform engineering, and finished-product data are never blurred together.
NAD+ Biology
01Peer-reviewed research on NAD+ metabolism, mitochondrial function, sirtuins, PARPs, and aging biology.
Delivery-System Science
02Published scientific research on thermosensitive gel systems, temperature-dependent phase transition, bioadhesive matrices, formulation residence, and controlled-release behavior.
GW Bio Health Platform Materials
03Technical documentation supplied by GW Bio Health concerning R3a, Cold Fusion™, SolGel, MitoJet™, and formulation engineering.
Finished Product Data
04Information appears here only if the exact Elev8 / GW 2250 mg NAD+ finished formulation was specifically tested. General NAD+ studies are never combined with finished-product evidence.
No finished-product testing has been published for this formulation yet.
For Researchers
Technical Formulation Rationale
Optional deep-dive — expand only the topics you need.
Frequently Asked
NAD+ Research Formulation, Explained
R3a Nano-Fusion™, Cold Fusion™, MitoJet™, and related technology names are associated with GW Bio Health and their respective intellectual-property owners. Elev8 Health is an authorized distribution and brand partner for the NAD+ technology. Product and technology information is provided for research and educational purposes.
For Research Use Only — Not For Human Or Veterinary Use
$135.00